Eli Lilly Presents Alzheimer’s Research at International Conference
NEC member Eli Lilly and Company (Lilly) recently presented new results from 17 studies at the Alzheimer’s Association International Conference, which was held virtually at the end of July. The data highlights Lilly’s programs focused on developing therapies that slow the progression of Alzheimers.
Lilly has been committed to ending Alzhiemers for almost 30 years and is a leader in identifying biomarkers to facilitate the early detection of Alzheimer’s cases, which lead to a timely and more accurate diagnosis. The therapies developed by Lilly seek to end the devastation of Alzheimers and find a cure to one of the top six diseases afflicting Americans.
“Lilly’s commitment to Alzheimer’s research continues with speed and collaboration to propel the science forward,” said John Sims, M.D., global brand development leader and senior medical director of Neurodegeneration. “The research findings we are sharing at this meeting are exciting and highlight our unwavering efforts to find solutions that may lead to a disease-modifying therapy, improve the ability to diagnose earlier in the disease progression, and advance our understanding of how the disease impacts those living with it.”
The New England Council applauds Eli Lilly and Company’s research successes in the pursuit of ending Alzhiemer’s. Read more at Eli Lilly and Company.